We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) (NASDAQ:CXSP) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive...
ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced today that new data from two clinical studies and one pre-clinical study with omacetaxine will be presented...
ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced today that updated clinical data from the registration-directed clinical trial of omacetaxine will be...
ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) (NASDAQ:CXSP) is pleased to announce the successful completion of a private placement to sophisticated and institutional...
Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online...
ChemGenex Pharmaceuticals (ASX:CXS)(NASDAQ:CXSP) has announced interim results from its ongoing phase 2/3 trial of omacetaxine mepesuccinate (formerly known as Ceflatonin?) in...
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today the publication of a report in the prestigious Nature publication Leukemia confirming the positive...
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the completion of an A$10.5 million capital raising achieved by a non-renounceable rights issue for 16,891,916...
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP), a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of...
MELBOURNE, Australia, and MENLO PARK, Calif., April 4 /PRNewswire- FirstCall/ -- ChemGenex Pharmaceuticals Limited (NASDAQ:CXSP)(ASX:CXS) announced today the presentation of three posters...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions